Icosapent ethyl (Vascepa): how it works, status and trials

ApprovedPillLowering triglycerides

In technical terms: Reduces liver VLDL-TG output; the cardiovascular benefit is larger than TG lowering alone explains.

The highlighted badge marks where Icosapent ethyl (Vascepa) acts. Open the full map or compare every therapy.

At a glance

Acts on: Multiple (liver TG synthesis, membranes)
How it is given: Oral EPA ethyl ester · 2 g twice daily
What the main trial found: MACE HR 0.75 (REDUCE-IT)
Status (curated October 25, 2026): Approved

Where it fits in the body

Triglyceride-rich lipoproteins

VLDL from the liver and chylomicrons from the gut carry triglyceride. Lipoprotein lipase (LPL) on capillary walls breaks it down. ANGPTL3 and apoC-III act as brakes on this process. Removing either brake (11–15) lowers triglycerides, and ANGPTL3 blockade also lowers LDL-C without needing LDL receptors, which matters in homozygous FH.

See it on the interactive map

Evidence

REDUCE-IT (PubMed 30415628)

Trials in our database

REDUCE-IT (2019): Benefit

Common questions

▸How does Icosapent ethyl (Vascepa) work?

Icosapent ethyl (Vascepa) is an EPA omega-3 taken as 2 g twice daily. It reduces the liver's output of triglyceride-rich particles, and its heart benefit in the REDUCE-IT trial was larger than triglyceride lowering alone explains. In technical terms: Reduces liver VLDL-TG output; the cardiovascular benefit is larger than TG lowering alone explains. It acts on Multiple (liver TG synthesis, membranes).

▸How much does Icosapent ethyl (Vascepa) lower cholesterol or other lipids?

MACE HR 0.75 (REDUCE-IT). Individual results differ, and a clinician can say what to expect for one person.

▸Is Icosapent ethyl (Vascepa) approved, and what is the status?

Approved (curated October 25, 2026).

▸How is Icosapent ethyl (Vascepa) taken?

Oral EPA ethyl ester · 2 g twice daily.

High Triglycerides: Causes and How to Lower Them

Related therapies

Evinacumab (Evkeeza): Approved 2021 (HoFH)
Olezarsen (Tryngolza) and volanesorsen: Olezarsen approved 2024; volanesorsen EU only
Plozasiran (Redemplo): Approved Nov 2025 (FCS)
Fibrates (fenofibrate): Approved (generic)

Not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed November 1, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. lipid.site is not a healthcare provider. Talk to your clinician before starting or stopping any treatment. If you have chest pain or signs of a stroke, call 911.